JustinPaulKlineMD

Associate Professor of Medicine, University of Chicago Medicine

Dr. Kline is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
5841 S Maryland Ave
# MC2115
Chicago, IL 60637
Phone+1 773-702-5550

Fax+1 773-702-3163

Dr. Justin Kline is an oncologist in Chicago, IL and is affiliated with University of Chicago Medical Center. He received his medical degree from University of Chicago Pritzker School of Medicine and has been in practice 16 years. He specializes in hematologic oncology and is experienced in hematologic oncology and stem cell transplantation.

University of ChicagoFellowship, Hematology and Medical Oncology, 2004 - 2007
University of ChicagoResidency, Internal Medicine, 2001 - 2004
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2001

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

PubMed

Journal Articles

CD8α+ Dendritic Cells Dictate Leukemia-Specific CD8+ T Cell Fates
Justin Kline, MD, The Journal of Immunology
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Mark P Chao, Sonali M Smith, Ranjana Advani, Ian Flinn, Ravindra Majeti, Nancy L Bartlett, Leslie Popplewell, Justin Kline, Nilanjan Ghosh, Ann LaCasce, The New England Journal of Medicine

Abstracts/Posters

Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCL
Justin Kline, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune Landscapes
Justin Kline, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS
Justin Kline, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Emerging Role of Immune Checkpoint Blockade in the Treatment of Refractory/Relapsed Hodgkin and Non-Hodgkin Lymphoma
60th American Society of Hematology Annual Meeting - 11/30/2018

ASCO Annual Meeting Returns to Chicago, Celebrates New Progress in CancerJune 15th, 2022
New Analysis of the Tumor Microenvironment Reveals 3 Subtypes in Large B-cell Lymphoma of the BrainSeptember 28th, 2020
‘Encouraging’ Responses Seen with Durvalumab plus R-CHOP in DLBCLJune 17th, 2019
Join now to see all